Our development of potent, oral, reversible ALDH1A3 inhibitors overcomes the prior undruggability of the retinoid nuclear receptor pathway and offers a distinct therapeutic approach to tumor immunotherapy and cardiovascular disease. This evidence concerns the gene ALDH1A3 and neoplasm.